These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 17939897)

  • 41. Varicella among adults: data from an active surveillance project, 1995-2005.
    Marin M; Watson TL; Chaves SS; Civen R; Watson BM; Zhang JX; Perella D; Mascola L; Seward JF
    J Infect Dis; 2008 Mar; 197 Suppl 2():S94-S100. PubMed ID: 18419417
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Immunization of adults against varicella and herpes zoster].
    Hanslik T; Blanchon T; Alvarez FP
    Rev Med Interne; 2007 Mar; 28(3):166-72. PubMed ID: 17270316
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program.
    Tanuseputro P; Zagorski B; Chan KJ; Kwong JC
    Vaccine; 2011 Nov; 29(47):8580-4. PubMed ID: 21939721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study.
    Baxter R; Ray P; Tran TN; Black S; Shinefield HR; Coplan PM; Lewis E; Fireman B; Saddier P
    Pediatrics; 2013 May; 131(5):e1389-96. PubMed ID: 23545380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Varicella: the vaccine and the public health debate.
    Niederhauser VP
    Nurse Pract; 1999 Mar; 24(3):74-6, 79, 83-4 passim. PubMed ID: 10100242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Live attenuated varicella vaccine.
    Arvin AM; Gershon AA
    Annu Rev Microbiol; 1996; 50():59-100. PubMed ID: 8905076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.
    Goldman GS; King PG
    Hum Exp Toxicol; 2014 Aug; 33(8):886-93. PubMed ID: 24275643
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Varicella vaccination: a laboured take-off.
    Carrillo-Santisteve P; Lopalco PL
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():86-91. PubMed ID: 24494784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Varicella vaccination in Australia and New Zealand.
    Macartney KK; Burgess MA
    J Infect Dis; 2008 Mar; 197 Suppl 2():S191-5. PubMed ID: 18419396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.
    Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
    van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
    Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Varicella vaccination of children in the United States: assessment after the first decade 1995-2005.
    Grose C
    J Clin Virol; 2005 Jun; 33(2):89-95; discussion 96-8. PubMed ID: 15911422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Varicella vaccination update].
    Nürnberg W; Schneeweiss B
    J Dtsch Dermatol Ges; 2006 Jul; 4(7):540-3. PubMed ID: 16827911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States.
    Patel MS; Gebremariam A; Davis MM
    Infect Control Hosp Epidemiol; 2008 Dec; 29(12):1157-63. PubMed ID: 18999945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Varicella-zoster virus disease and epidemiology: seeking better control strategies--Part 1.
    Bentsi-Enchill A
    Can Commun Dis Rep; 1998 Dec; 24(24):193-8. PubMed ID: 9916347
    [No Abstract]   [Full Text] [Related]  

  • 56. Varicella outbreak epidemiology in an active surveillance site, 1995-2005.
    Civen R; Lopez AS; Zhang J; Garcia-Herrera J; Schmid DS; Chaves SS; Mascola L
    J Infect Dis; 2008 Mar; 197 Suppl 2():S114-9. PubMed ID: 18419383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005.
    Chaves SS; Haber P; Walton K; Wise RP; Izurieta HS; Schmid DS; Seward JF
    J Infect Dis; 2008 Mar; 197 Suppl 2():S170-7. PubMed ID: 18419393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changing varicella epidemiology in active surveillance sites--United States, 1995-2005.
    Guris D; Jumaan AO; Mascola L; Watson BM; Zhang JX; Chaves SS; Gargiullo P; Perella D; Civen R; Seward JF
    J Infect Dis; 2008 Mar; 197 Suppl 2():S71-5. PubMed ID: 18419413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy.
    Gialloreti LE; Divizia M; Pica F; Volpi A
    Herpes; 2005 Oct; 12(2):33-7. PubMed ID: 16209858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008.
    Chao DY; Chien YZ; Yeh YP; Hsu PS; Lian IB
    Epidemiol Infect; 2012 Jun; 140(6):1131-40. PubMed ID: 21906410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.